Company Announcements

Diaceutics PLC

Issue of Share Options/PDMR Shareholdings

Belfast and London, 29 July 2024- Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces the issue of 1,494,051 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP") on 23 July 2024. These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.

Share Options were granted as to PDMRs follows:

A further 790,927 Share Options were granted to a total of 53 other employees.

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and recurring revenue. The average mid-market closing share price in the three days prior to the issue of the Share Options was £1.33. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the Company is 4,711,454 representing approximately 5.56% of its current issued share capital of 84,720,076.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.